AK119

DRUG7 trials

Sponsors

Akesobio Australia Pty Ltd, Akeso

Conditions

Advanced or Metastatic Solid TumorsColorectal CancerCoronavirus Disease 2019 (COVID-19)NSCLCSolid TumorSolid Tumor, Adult

Phase 1

A Study of AK119 (Anti-CD73 Antibody), a Treatment for COVID-19, in Healthy Subjects

CompletedNCT04516564

Akesobio Australia Pty LtdCoronavirus Disease 2019 (COVID-19)

Start: 2020-09-28End: 2021-06-21Updated: 2025-02-28

A Study of AK119 (Anti-CD73) in Combination With AK104 in Subjects With Advanced Solid Tumors

CompletedNCT04572152

AkesoAdvanced or Metastatic Solid Tumors

Start: 2020-12-07End: 2023-08-31Updated: 2025-02-28

Study of AK119 in Subjects With Advanced Solid Tumors

CompletedNCT05173792

AkesoSolid Tumor

Start: 2021-12-22End: 2023-05-22Updated: 2024-04-25

Study of AK119 Combined With AK104 in Patients With Advanced Solid Tumors

TerminatedNCT05559541

AkesoSolid Tumor, Adult

Start: 2022-12-15End: 2024-05-31Updated: 2025-02-19

Study of AK119 and AK112 With or Without Chemotherapy for NSCLC Patients

TerminatedNCT05636267

Start: 2023-02-10End: 2025-04-15Updated: 2026-03-09

Study of AK119 Combined With AK112 in Patients With Advanced Solid Tumors

RecruitingNCT05689853

AkesoSolid Tumor, Adult

Start: 2023-04-14End: 2027-06-01Target: 87Updated: 2026-03-18

A Phase Ib/II Clinical Study on AK112 Combined or Not Combined With AK119 in pMMR/MSS Colorectal Cancer

Active, not recruitingNCT05846867

AkesoColorectal Cancer

Start: 2023-05-08End: 2026-08-11Target: 170Updated: 2026-03-04

Related Papers

A phase I study of AK119, an anti-CD73 monoclonal antibody, in combination with AK104, an anti-PD-1/CTLA-4 bispecific antibody, in patients with advanced or metastatic solid tumors.

Journal of Clinical Oncology2021-05-205 citations

476 AK119, a humanized anti-CD73 monoclonal antibody, as Immunotherapy for COVID-19

Regular and Young Investigator Award Abstracts2020-11-015 citations